Use of determination of drug levels to optimize pharmacotherapy of heart failure

Conditions

Chronic heart failure with reduced ejection fraction

Brief summary

To determine whether in patients with chronic heart failure with reduced ejection fraction (HFrEF) the serum concentration of the drugs used is more important than the dose of these drugs (beta-blockers bisoprolol, carvedilol, metoprolol succinate or nebivolol; spironolactone, sacubitril, valsartan) for compensating the health status)

Detailed description

To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the values of selected clinical indicators (NT-proBNP concentration, 6-minute walk test, quality of life questionnaire, echocardiographic parameters, hospitalization for HFrEF, length of survival) is demonstrated., To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the adverse effects of these drugs is demonstrated, To determine the number of patients in whom non-adherence to treatment will be demonstrated

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGNEBIVOLOL

DRUGCARVEDILOL

DRUGBISOPROLOL FUMARATE

DRUGSPIRONOLACTONE

DRUGSACUBITRIL VALSARTAN

DRUGMETOPROLOL SUCCINATE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To determine whether in patients with chronic heart failure with reduced ejection fraction (HFrEF) the serum concentration of the drugs used is more important than the dose of these drugs (beta-blockers bisoprolol, carvedilol, metoprolol succinate or nebivolol; spironolactone, sacubitril, valsartan) for compensating the health status)	—

Secondary

Measure	Time frame
To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the values of selected clinical indicators (NT-proBNP concentration, 6-minute walk test, quality of life questionnaire, echocardiographic parameters, hospitalization for HFrEF, length of survival) is demonstrated., To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the adverse effects of these drugs is demonstrated, To determine the number of patients in whom non-adherence to treatment will be demonstrated	—

Measure

Time frame

To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the values of selected clinical indicators (NT-proBNP concentration, 6-minute walk test, quality of life questionnaire, echocardiographic parameters, hospitalization for HFrEF, length of survival) is demonstrated., To determine the number of patients in whom a significant dependence between the serum concentration of the mentioned drugs and the adverse effects of these drugs is demonstrated, To determine the number of patients in whom non-adherence to treatment will be demonstrated

—

Countries

Czechia

Outcome results

None listed